Shingles drug may capture half the market, Decision Resources predicts Decision Resources projects more than 150% growth in multiple myeloma market Citing potential problems, FDA declines to approve A.P. Pharma drug NHVR: Increased funding needed for viral hepatitis screening, intervention WASHINGTON “Systemic underfunding” at the Centers for Disease Control and Prevention’s Division of Viral Hepatitis puts the health of millions of Americans with viral hepatitis at risk, a group of organizations focused on the disease said this week. High doses of cholesterol drug may raise muscle injury risk, FDA warns Merck, Portola release results of mid-stage betrixaban trial Pfizer presents efficacy data of Prevenar 13 at conference FDA approves Carbaglu Roche calls its R&D status 'uniquely positioned' The Medicines Co. recalls lots of Cleviprex First Previous 205 206 207 208 209 Next Last
